Autologous bone marrow transplantation for pediatric Wilms' tumor: The experience of the European Bone Marrow Transplantation Solid Tumor Registry

A. Garaventa, O. Hartmann, J. L. Bernard, J. M. Zucker, N. Pardo, V. Castel, S. Dallorso, Z. Adelbost, R. Ladenstein, F. Chauvin, T. Phillip

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

This survey includes 25 children with Wilms' tumor undergoing high-dose chemotherapy associated with autologous bone marrow transplantation (ABMT) in the period June 1984-December 1991 and enrolled in the European Bone Marrow Transplantation Registry for Solid Tumors. At diagnosis, 12 children presented stage IV disease, 5 stage III, 3 stage II, and 5 stage I. Before ABMT, 21 children had 1 to 4 relapses (median 1); 13 achieved a second or subsequent complete remission (CR), four stage IV children failed to respond to first line treatment and achieved either CR (3 patients), or partial remission (PR) after second line therapy. At high-dose chemotherapy, 17 children were in CR and 8 had measurable disease. Seven different high-dose regimens were administered, even if 20 children received melphalan mostly associated with vincristine and 8 involved field radiotherapy. Three children died early of pneumonitis; 2 developed an acute transient renal failure, 1 a chronic renal failure. Out of the 8 children with target disease at graft, 2 died of toxicity, 5 achieved CR, 1 obtained PR, and only 1 is presently alive in CCR at 39 months after ABMT. Of the 17 children grafted in CR, 8 are alive event-free at 14-90 months (median 34) from ABMT; 7 relapsed at 3-23 months (median 7 months); 1 died of toxicity and 1 was lost to follow-up in CR at 12 months. A salvage attempt with high-dose chemotherapy in children with resistant or poor prognosis recurrent Wilms' tumor seems to be justified. An international cooperative protocol taking into account the increased risk of lung and renal toxicity is necessary.

Original languageEnglish
Pages (from-to)11-14
Number of pages4
JournalMedical and Pediatric Oncology
Volume22
Issue number1
DOIs
Publication statusPublished - 1994

Fingerprint

Wilms Tumor
Autologous Transplantation
Bone Marrow Transplantation
Registries
Pediatrics
Neoplasms
Drug Therapy
Melphalan
Lost to Follow-Up
Vincristine
Acute Kidney Injury
Chronic Kidney Failure
Pneumonia
Radiotherapy
Transplants
Kidney
Recurrence
Lung

Keywords

  • autologous bone marrow transplantation
  • high-dose chemotherapy
  • nephroblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Autologous bone marrow transplantation for pediatric Wilms' tumor : The experience of the European Bone Marrow Transplantation Solid Tumor Registry. / Garaventa, A.; Hartmann, O.; Bernard, J. L.; Zucker, J. M.; Pardo, N.; Castel, V.; Dallorso, S.; Adelbost, Z.; Ladenstein, R.; Chauvin, F.; Phillip, T.

In: Medical and Pediatric Oncology, Vol. 22, No. 1, 1994, p. 11-14.

Research output: Contribution to journalArticle

Garaventa, A. ; Hartmann, O. ; Bernard, J. L. ; Zucker, J. M. ; Pardo, N. ; Castel, V. ; Dallorso, S. ; Adelbost, Z. ; Ladenstein, R. ; Chauvin, F. ; Phillip, T. / Autologous bone marrow transplantation for pediatric Wilms' tumor : The experience of the European Bone Marrow Transplantation Solid Tumor Registry. In: Medical and Pediatric Oncology. 1994 ; Vol. 22, No. 1. pp. 11-14.
@article{35eb96aea82b467e871a4b80a195288b,
title = "Autologous bone marrow transplantation for pediatric Wilms' tumor: The experience of the European Bone Marrow Transplantation Solid Tumor Registry",
abstract = "This survey includes 25 children with Wilms' tumor undergoing high-dose chemotherapy associated with autologous bone marrow transplantation (ABMT) in the period June 1984-December 1991 and enrolled in the European Bone Marrow Transplantation Registry for Solid Tumors. At diagnosis, 12 children presented stage IV disease, 5 stage III, 3 stage II, and 5 stage I. Before ABMT, 21 children had 1 to 4 relapses (median 1); 13 achieved a second or subsequent complete remission (CR), four stage IV children failed to respond to first line treatment and achieved either CR (3 patients), or partial remission (PR) after second line therapy. At high-dose chemotherapy, 17 children were in CR and 8 had measurable disease. Seven different high-dose regimens were administered, even if 20 children received melphalan mostly associated with vincristine and 8 involved field radiotherapy. Three children died early of pneumonitis; 2 developed an acute transient renal failure, 1 a chronic renal failure. Out of the 8 children with target disease at graft, 2 died of toxicity, 5 achieved CR, 1 obtained PR, and only 1 is presently alive in CCR at 39 months after ABMT. Of the 17 children grafted in CR, 8 are alive event-free at 14-90 months (median 34) from ABMT; 7 relapsed at 3-23 months (median 7 months); 1 died of toxicity and 1 was lost to follow-up in CR at 12 months. A salvage attempt with high-dose chemotherapy in children with resistant or poor prognosis recurrent Wilms' tumor seems to be justified. An international cooperative protocol taking into account the increased risk of lung and renal toxicity is necessary.",
keywords = "autologous bone marrow transplantation, high-dose chemotherapy, nephroblastoma",
author = "A. Garaventa and O. Hartmann and Bernard, {J. L.} and Zucker, {J. M.} and N. Pardo and V. Castel and S. Dallorso and Z. Adelbost and R. Ladenstein and F. Chauvin and T. Phillip",
year = "1994",
doi = "10.1002/mpo.2950220103",
language = "English",
volume = "22",
pages = "11--14",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Autologous bone marrow transplantation for pediatric Wilms' tumor

T2 - The experience of the European Bone Marrow Transplantation Solid Tumor Registry

AU - Garaventa, A.

AU - Hartmann, O.

AU - Bernard, J. L.

AU - Zucker, J. M.

AU - Pardo, N.

AU - Castel, V.

AU - Dallorso, S.

AU - Adelbost, Z.

AU - Ladenstein, R.

AU - Chauvin, F.

AU - Phillip, T.

PY - 1994

Y1 - 1994

N2 - This survey includes 25 children with Wilms' tumor undergoing high-dose chemotherapy associated with autologous bone marrow transplantation (ABMT) in the period June 1984-December 1991 and enrolled in the European Bone Marrow Transplantation Registry for Solid Tumors. At diagnosis, 12 children presented stage IV disease, 5 stage III, 3 stage II, and 5 stage I. Before ABMT, 21 children had 1 to 4 relapses (median 1); 13 achieved a second or subsequent complete remission (CR), four stage IV children failed to respond to first line treatment and achieved either CR (3 patients), or partial remission (PR) after second line therapy. At high-dose chemotherapy, 17 children were in CR and 8 had measurable disease. Seven different high-dose regimens were administered, even if 20 children received melphalan mostly associated with vincristine and 8 involved field radiotherapy. Three children died early of pneumonitis; 2 developed an acute transient renal failure, 1 a chronic renal failure. Out of the 8 children with target disease at graft, 2 died of toxicity, 5 achieved CR, 1 obtained PR, and only 1 is presently alive in CCR at 39 months after ABMT. Of the 17 children grafted in CR, 8 are alive event-free at 14-90 months (median 34) from ABMT; 7 relapsed at 3-23 months (median 7 months); 1 died of toxicity and 1 was lost to follow-up in CR at 12 months. A salvage attempt with high-dose chemotherapy in children with resistant or poor prognosis recurrent Wilms' tumor seems to be justified. An international cooperative protocol taking into account the increased risk of lung and renal toxicity is necessary.

AB - This survey includes 25 children with Wilms' tumor undergoing high-dose chemotherapy associated with autologous bone marrow transplantation (ABMT) in the period June 1984-December 1991 and enrolled in the European Bone Marrow Transplantation Registry for Solid Tumors. At diagnosis, 12 children presented stage IV disease, 5 stage III, 3 stage II, and 5 stage I. Before ABMT, 21 children had 1 to 4 relapses (median 1); 13 achieved a second or subsequent complete remission (CR), four stage IV children failed to respond to first line treatment and achieved either CR (3 patients), or partial remission (PR) after second line therapy. At high-dose chemotherapy, 17 children were in CR and 8 had measurable disease. Seven different high-dose regimens were administered, even if 20 children received melphalan mostly associated with vincristine and 8 involved field radiotherapy. Three children died early of pneumonitis; 2 developed an acute transient renal failure, 1 a chronic renal failure. Out of the 8 children with target disease at graft, 2 died of toxicity, 5 achieved CR, 1 obtained PR, and only 1 is presently alive in CCR at 39 months after ABMT. Of the 17 children grafted in CR, 8 are alive event-free at 14-90 months (median 34) from ABMT; 7 relapsed at 3-23 months (median 7 months); 1 died of toxicity and 1 was lost to follow-up in CR at 12 months. A salvage attempt with high-dose chemotherapy in children with resistant or poor prognosis recurrent Wilms' tumor seems to be justified. An international cooperative protocol taking into account the increased risk of lung and renal toxicity is necessary.

KW - autologous bone marrow transplantation

KW - high-dose chemotherapy

KW - nephroblastoma

UR - http://www.scopus.com/inward/record.url?scp=0028366250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028366250&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950220103

DO - 10.1002/mpo.2950220103

M3 - Article

C2 - 8232074

AN - SCOPUS:0028366250

VL - 22

SP - 11

EP - 14

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -